🔎 Trials Near Me

Beranda › Kanker Laring › New York

Uji klinis Kanker Laring di New York

10 studi untuk Kanker Laring mencari peserta di lokasi di New York.

Kota di New York

Teks studi resmi (Bahasa Inggris)

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  • University of Rochester, Rochester
  • Stony Brook University Medical Center, Stony Brook
  • Wilmot Cancer Institute at Webster, Webster
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07195734

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06589804

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  • NYU Langone Hospital - Long Island, Mineola
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

  • Montefiore Medical Center-Einstein Campus, The Bronx
  • Montefiore Medical Center - Moses Campus, The Bronx
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05172245

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • Northwell Health Imbert Cancer Center, Bay Shore
  • Northwell Health/Center for Advanced Medicine, Lake Success
  • Long Island Jewish Medical Center, New Hyde Park
  • dan 5 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

  • Montefiore Medical Center-Einstein Campus, The Bronx
  • Montefiore Medical Center - Moses Campus, The Bronx
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

  • Stony Brook University Medical Center, Stony Brook
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07441681

Integrated Cancer Repository for Cancer Research

  • C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
  • Faxton St. Luke's Healthcare, Mohawk Valley, Utica
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

  • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT07063212

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Buffalo
  • Massive Bio SYNERGY-AI site, Hempstead
  • Massive Bio SYNERGY-AI site, Manhasset
  • dan 2 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.